Development of Natural Product Inspired Adjuvants to Treat Tolerant Infections
开发受天然产物启发的佐剂来治疗耐受性感染
基本信息
- 批准号:10153695
- 负责人:
- 金额:$ 28.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-01 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAnti-Bacterial AgentsAntibioticsBacteriaBacterial InfectionsBiologicalBiological AssayBreathingBudgetsCellsChemicalsClinicClinicalClinical TreatmentCollaborationsCommunicable DiseasesDataDevelopmentDiagnosisDoseDoxycyclineDrug KineticsDrug resistanceFamilyFundingFutureGoalsGram-Positive Bacterial InfectionsGrantHandHumanIn VitroInfectionInvestigational New Drug ApplicationJointsLeadLibrariesMedicineMicrobial BiofilmsMicrobiologyModelingNatural ProductsOperative Surgical ProceduresOrthopedic SurgeryOrthopedicsOxazolidinonesPharmaceutical ChemistryPharmaceutical PreparationsPhasePreparationProcessPropertyScienceSiteSourceStaphylococcus aureusTherapeuticTriageVancomycinWorkanalogantimicrobialbasecommercializationdrug developmenthigh throughput screeningimprovedin vivojoint infectionmarine natural productmicroorganismmouse modelnovelnovel therapeuticspathogenpreclinical studypreventscaffoldscreeningsmall moleculestandard of caresynergism
项目摘要
Project Summary
Natural products have served as a productive source of drugs over the past decades and have
represented, or been the inspiration for, a majority of antimicrobial compounds that have entered
the clinic. The goal of this proposal is to develop novel antibacterial adjuvants based on the marine
natural product synoxazolidinone B to treat Gram-positive orthopedic joint infections. These
scaffolds have the potential to clear biofilm-implicated recalcitrant infections based on preliminary
in-vitro data. These biofilm-implicated infections are tolerant to traditional antibiotics and represent
a significant clinical need since up to 80% of human infections involve biofilm-associated
microorganisms. Few small molecules have been isolated that have the potential to disrupt
biofilms, thereby functioning to clear biofilm associated infections. Herein, we propose to develop
a class of compounds that is capable to addressing the treatment of biofilm associated infections
and generate the key data necessary for a go/no-go decision to advance these molecules toward
a Phase II pre-clinical study.
项目摘要
在过去的几十年里,天然产品一直是药物的生产来源,
代表了大多数已进入的抗菌化合物,或者是其灵感来源
诊所该提案的目标是开发基于海洋生物的新型抗菌佐剂
天然产物synoxazolidinone B用于治疗革兰氏阳性骨科关节感染。这些
支架具有清除生物膜相关的寄生虫感染的潜力,
体外数据。这些与生物膜有关的感染对传统抗生素具有耐受性,
由于高达80%的人类感染涉及生物膜相关的
微生物的很少有小分子被分离出来,有可能破坏
生物膜,从而起到清除生物膜相关感染的作用。在此,我们建议开发
一类能够治疗生物膜相关感染的化合物
并生成必要的关键数据,用于决定是否将这些分子推向
a II期临床前研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joshua G. Pierce其他文献
Synthesis reveals unexpected biological targets of a traditional medicine
合成揭示了传统药物的意想不到的生物靶点
- DOI:
10.1038/d41586-022-01740-w - 发表时间:
2022-06-27 - 期刊:
- 影响因子:48.500
- 作者:
Nicholas P. R. Onuska;Joshua G. Pierce - 通讯作者:
Joshua G. Pierce
Pyrrolidine-2,3-diones: heterocyclic scaffolds that inhibit and eradicate emS. aureus/em biofilms
吡咯烷-2,3-二酮:抑制和根除金黄色葡萄球菌生物膜的杂环支架
- DOI:
10.1039/d4cc02708f - 发表时间:
2024-09-18 - 期刊:
- 影响因子:4.200
- 作者:
M. Alejandro Valdes-Pena;Andrew Ratchford;Minhua Nie;Lauren V. Schnabel;Joshua G. Pierce - 通讯作者:
Joshua G. Pierce
Examining ubiquitinated peptide enrichment efficiency through an epitope labeled protein.
通过表位标记的蛋白质检查泛素化肽富集效率。
- DOI:
10.1016/j.ab.2016.08.017 - 发表时间:
2016 - 期刊:
- 影响因子:2.9
- 作者:
Jennifer Parker;Yeonyee Oh;Y. Moazami;Joshua G. Pierce;Philip L. Loziuk;Ralph A. Dean;D. Muddiman - 通讯作者:
D. Muddiman
Joshua G. Pierce的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joshua G. Pierce', 18)}}的其他基金
NC State Chemistry of Life Training Program (CLTP)
北卡罗来纳州立大学生命化学培训计划 (CLTP)
- 批准号:
10206905 - 财政年份:2021
- 资助金额:
$ 28.38万 - 项目类别:
Synthesis and Chemical Biology of Bioactive Natural Products
生物活性天然产物的合成与化学生物学
- 批准号:
10320343 - 财政年份:2021
- 资助金额:
$ 28.38万 - 项目类别:
Synthesis and Chemical Biology of Bioactive Natural Products
生物活性天然产物的合成与化学生物学
- 批准号:
10540632 - 财政年份:2021
- 资助金额:
$ 28.38万 - 项目类别:
Synthesis and Chemical Biology of Bioactive Natural Products
生物活性天然产物的合成与化学生物学
- 批准号:
10541832 - 财政年份:2021
- 资助金额:
$ 28.38万 - 项目类别:
Synthesis and Chemical Biology of Bioactive Natural Products
生物活性天然产物的合成与化学生物学
- 批准号:
10362020 - 财政年份:2021
- 资助金额:
$ 28.38万 - 项目类别:
NC State Chemistry of Life Training Program (CLTP)
北卡罗来纳州立大学生命化学培训计划 (CLTP)
- 批准号:
10410434 - 财政年份:2021
- 资助金额:
$ 28.38万 - 项目类别:
NC State Chemistry of Life Training Program (CLTP)
北卡罗来纳州立大学生命化学培训计划 (CLTP)
- 批准号:
10645140 - 财政年份:2021
- 资助金额:
$ 28.38万 - 项目类别:
Synthesis and Chemical Biology of Bioactive Natural Products
生物活性天然产物的合成与化学生物学
- 批准号:
10592843 - 财政年份:2021
- 资助金额:
$ 28.38万 - 项目类别:
Synthesis and Chemical Biology of Bioactive Natural Products
生物活性天然产物的合成与化学生物学
- 批准号:
10728370 - 财政年份:2021
- 资助金额:
$ 28.38万 - 项目类别:
Development of Single Agent Antibiofilm Antibiotics
单剂抗生物膜抗生素的研制
- 批准号:
10189520 - 财政年份:2020
- 资助金额:
$ 28.38万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 28.38万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 28.38万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 28.38万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 28.38万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 28.38万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 28.38万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 28.38万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 28.38万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 28.38万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 28.38万 - 项目类别: